scispace - formally typeset
H

Howard N. Hodis

Researcher at University of Southern California

Publications -  318
Citations -  24700

Howard N. Hodis is an academic researcher from University of Southern California. The author has contributed to research in topics: Menopause & Intima-media thickness. The author has an hindex of 74, co-authored 297 publications receiving 22233 citations. Previous affiliations of Howard N. Hodis include Oklahoma Medical Research Foundation.

Papers
More filters
Journal ArticleDOI

Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial

TL;DR: Estradiol treatment is beneficial in preventing progression of atherosclerosis in postmenopausal women not receiving lipid-lowering therapy, regardless of their initial body mass index.
Journal ArticleDOI

Correction: Ambient Air Pollution and the Progression of Atherosclerosis in Adults

TL;DR: This research presents a probabilistic analysis of the immune system’s response to repeated exposure to carbon monoxide poisoning and shows clear patterns of decline in men and women aged between the ages of 18 and 74.
Journal ArticleDOI

HRT and breast cancer risk: a realistic perspective.

TL;DR: Concerns over the validity of their statistical analyses and the clinical relevance and applicability of their findings are questioned, as the data over the 11 years show no increased risk of breast cancer with CEE/MPA in women who had not previously used hormone replacement therapy (HRT).
Journal ArticleDOI

Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: implications for late onset Alzheimer's disease.

TL;DR: In a general population of postmenopausal women, association between poor metabolic profile with reduction in cognitive performance is more apparent in women who carry an ApoE4 allele, indicating a window of opportunity for interventions to reverse the trajectory of the preclinical phase of Alzheimer's disease.